DUPILUMAB
Dupilumab is a monoclonal antibody used for the treatment of certain inflammatory conditions. It specifically targets the interleukin-4 receptor alpha subunit, thereby modulating the immune response. Dupilumab is an interleukin-4 receptor alpha antagonist.-Atopic dermatitis (eczema): Dupilumab is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents who are not adequately controlled with topical prescription therapies or when those treatments are not advisable. -Asthma: Dupilumab is also used to treat moderate to severe asthma in adults and adolescents who have an eosinophilic phenotype or with oral corticosteroid-dependent asthma. -Atopic Dermatitis DUPILUMAB is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPILUMAB can be used with or without topical corticosteroids. Asthma DUPILUMAB is indicated as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid-dependent asthma. DUPILUMAB is not indicated for the relief of acute bronchospasm or status asthmaticus. Chronic Rhinosinusitis with Nasal Polyposis DUPILUMAB is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP). Eosinophilic Esophagitis DUPILUMAB is indicated for the treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis (EoE). Prurigo Nodularis DUPILUMAB is indicated for the treatment of adult patients with prurigo nodularis (PN).
-The recommended dosage may vary based on the specific indication and patient characteristics. Consult a healthcare professional for individualized dosing. -Subcutaneous; prefilled injections Atopic Dermatitis Adult Dosage The recommended dosage is an initial dose of 600 mg (two 300 mg injections), followed by 300 mg every other week. -Asthma Dosage in Adult and Pediatric Patients 12 Years and Older: The initial Loading Dose is 400 mg (two 200 mg injections) and the Subsequent Dosage is 200 mg every 2 weeks Chronic Rhinosinusitis with Nasal Polyposis : The recommended dosage for adult patients is 300 mg given every other week. Eosinophilic Esophagitis: The recommended dosage for adult and pediatric patients 12 years of age and older, weighing at least 40 kg, is 300 mg every week. Prurigo Nodularis : The recommended dosage for adult patients is an initial dose of 600 mg (two 300 mg injections), followed by 300 mg given every other week.
-Hypersensitivity: Dupilumab is contraindicated in individuals with known hypersensitivity to the drug or any of its components. -Hypersensitivity
-Infections: Patients should be monitored for signs of infections while on dupilumab therapy. -Vaccinations: Live vaccines should be avoided during treatment. -Eosinophilic conditions: Caution is advised in patients with pre-existing eosinophilic conditions. -Paediatric: Safety and efficacy in pediatric age group of less than 6 months have not been established Pregnancy:Data not sufficient Lactation: Data not sufficient. Elderly: Data not sufficient.
-Common side effects may include injection site reactions, conjunctivitis, and upper respiratory tract infections. Serious side effects may include hypersensitivity reactions, including anaphylaxis, and eosinophilia. -Injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, eosinophilia, oropharyngeal pain,insomnia, toothache, gastritis, arthralgia, upper respiratory tract infection, dizziness, myalgia, and diarrhoea
No formal drug interaction studies have been conducted with dupilumab. However, caution should be exercised when co-administering immunosuppressive agents.
